![](/wp-content/uploads/2018/10/ANdEdYbxR5KQXilm0B30.png)
$599
New Ph1 Trial for Novartis’s BCMA CAR-T PHE885 Using a New Manufacturing Method
A new Novartis-sponsored Ph1 trial has been detected for the BCMA CAR-T, PHE885, in ≥3L relapsed and refractory multiple myeloma (RRMM). Of note, the trial uses a new CAR-T manufacturing method. Below, FENIX provides insights on this new trial and how a potentially improved manufacturing process could enhance Novartis’s position compared to the BCMA CAR-T leaders, BMS and Janssen.